Stock PHARM PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Pharming Group N.V. Share Price

Equities

PHARM

NL0010391025

Pharmaceuticals

Market Closed - Euronext Amsterdam
Other stock markets
 16:35:00 26/04/2024 BST 		5-day change 1st Jan Change
0.9 EUR +2.16% Intraday chart for Pharming Group N.V. +2.16% -12.71%
04-22 Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
04-18 Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT

Financials

Sales 2024 * 262M 280M 22.44B Sales 2025 * 300M 321M 25.73B Capitalization 606M 648M 51.9B
Net income 2024 * 1M 1.07M 85.62M Net income 2025 * 14M 14.97M 1.2B EV / Sales 2024 * 1.97 x
Net cash position 2024 * 90.86M 97.15M 7.78B Net cash position 2025 * 119M 128M 10.23B EV / Sales 2025 * 1.62 x
P/E ratio 2024 *
-300 x
P/E ratio 2025 *
40.9 x
Employees 382
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.66%
More Fundamentals * Assessed data

Chart Pharming Group N.V.

Dynamic Chart

Latest news about Pharming Group N.V.

Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024 CI
Pharming Group Seeks Acquisitions CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024 MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment MT
More news

Latest transcript on Pharming Group N.V.

Logo Pharming Group N.V.
Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
More transcripts

Analyst Recommendations on Pharming Group N.V.

RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating MT
Oppenheimer Adjusts Pharming Group Price Target to $40 From $36, Maintains Outperform Rating MT
Oppenheimer Adjusts Pharming Group's Price Target to $36 From $43, Maintains Outperform Rating MT
Van Leeuwenhoeck issues research note on Pharming (PHAR.AS): Turning the Page PU
More recommendations

Press releases Pharming Group N.V.

Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K PU
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders 2024 Rare Impact Awards AQ
Pharming N : to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards - Form 6-K PU
Pharming N : Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards PU
Pharming Group to report first quarter 2024 financial results on May 8 GL
More press releases

News in other languages on Pharming Group N.V.

AEX in het groen ondanks koersval Akzo en Randstad
Prosus geeft impuls aan AEX
AEX weet openingswinst vast te houden
AEX start handelsweek naar verwachting in het groen
Rentevrees en geopolitiek duwen AEX weg van record
More news

Quotes and Performance

1 day+2.16%
1 week+2.16%
Current month-11.68%
1 month-11.07%
3 months-22.48%
6 months-17.81%
Current year-12.71%
More quotes

Highs and lows

1 week
0.88
Extreme 0.875
0.92
1 month
0.86
Extreme 0.861
1.03
Current year
0.86
Extreme 0.861
1.22
1 year
0.86
Extreme 0.861
1.31
3 years
0.66
Extreme 0.6576
1.42
5 years
0.66
Extreme 0.6576
1.64
10 years
0.15
Extreme 0.15
1.64
More quotes

Managers and Directors - Pharming Group N.V.

Managers TitleAgeSince
Sijmen de Vries CEO
 Chief Executive Officer 65 12/10/08
Jeroen Wakkerman DFI
 Director of Finance/CFO 55 15/11/20
Anurag Relan CTO
 Chief Tech/Sci/R&D Officer 52 -
Members of the board TitleAgeSince
Mark Pykett BRD
 Director/Board Member 60 10/12/20
Leonard Kruimer BRD
 Director/Board Member 66 18/05/21
Sijmen de Vries CEO
 Chief Executive Officer 65 12/10/08
More insiders

ETFs positioned on Pharming Group N.V.

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.17% 2 M€ -.--%
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.05% 7 M€ -.--% -
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD ETF SPDR MSCI World Small Cap UCITS ETF - USD
0.02% 773 M€ -.--% -
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.01% 10 M€ -3.35% -
More ETFs positioned on Pharming Group N.V.

Quotes

Date Price Change Volume
26/04/24 0.9 +2.16% 3,641,122
25/04/24 0.881 -2.60% 4,203,859
24/04/24 0.9045 -0.39% 6,519,524
23/04/24 0.908 +0.89% 4,300,077
22/04/24 0.9 +2.16% 6,570,354

Real-time Euronext Amsterdam, April 26, 2024 at 04:35 pm

More quotes

Company Profile

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
08/05/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Pharming Group N.V.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9 EUR
Average target price
2 EUR
Spread / Average Target
+122.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMING GROUP N.V. Stock Pharming Group N.V.
-12.71% 647M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHARM Stock